16 results about "Mouse Nerve" patented technology

The invention relates to an in vitro method of generating a murine cerebral organoid cell culture model, comprising cultivating murine neural stem cells obtained from an adult mouse until neurospheres have formed, and subsequently differentiating said neurospheres, thereby generating a murine cerebral organoid cell culture model. The invention further relates to an in vitro murine cerebral organoid cell culture model comprising mature astrocytes, oligodendrocytes and / or neurons produced according to the method of the invention and its use for drug or toxicity screenings or for studying neurological diseases. In other aspects the invention further relates to kits, cell culture media and supplement compositions comprising components to be used in the context of the present invention.

The invention provides a mouse neuron network construction method and system based on two-photon imaging, and the method comprises the steps: collecting neuron imaging data through a two-photon calcium imaging system, and extracting a fluorescence change time sequence of each neuron from the neuron imaging data; constructing a function connection matrix according to the fluorescence change time sequence, and then calculating a small world coefficient and a network core degree of the neural network based on the function connection matrix; and based on the small-world coefficient and the network core degree, using a liquid state machine to establish a brain-like neuron network. The problems that in the prior art, the network connection mode between single neurons cannot be researched at the cellular level, and effective simulation of a spatial-temporal information processing mechanism of a biological nervous system is lacked are solved.

The invention discloses application of mitochondrion Rab32 in preparation of a medicine for treating chronic sleep deprivation and a research method of the mitochondrion Rab32, and belongs to the technical field of biological medicine. A chronic sleep deprivation mouse model is established, the relationship between mitochondria Rab32 and in-vivo protein change of an SD mouse is researched, and the result shows that the mitochondria Rab32 participates in cytoskeleton protein function regulation and control and participates in neuronal synaptic regeneration by anchoring Sptan1 in cells. Rab32 is a key molecule for mediating neuron synaptic regeneration of SD mice and adjusting synaptic plasticity and cognitive impairment, and the research result may provide a new target for treatment of SD-related cognitive impairment in future.

The present application provides a compound for treating Alzheimer's disease designed based on artificial intelligence, a preparation method and medical uses thereof. The compound is shown as formula I. Through pharmacological experiments, it is found that compounds 548 and 398 both have the effect of inhibiting LPS-induced neuroinflammation, in addition, compound 548 can improve LPS lateral ventricle injection mouse neuroinflammation, improve Aβ 1‑42 Lateral ventricle injection mouse neuroinflammatory injury, so the compound shown as formula I can be used for preparing a drug for treating Alzheimer's disease.

This invention discloses a *Ligilactobacillus salivarius* YS-SA09, with accession number CGMCC NO.37763 and Latin name *Ligilactobacillus salivarius*. This invention also discloses a *Citrus aurantium* ferment, obtained by fermenting *Citrus aurantium* with the aforementioned *Ligilactobacillus salivarius* YS-SA09. This invention further discloses the applications of *Ligilactobacillus salivarius* YS-SA09 and the *Citrus aurantium* ferment, which can effectively improve sleep in mice with insomnia models, effectively shorten sleep latency, and prolong sleep onset time; effectively improve depressive-like behavior in mice with CUMS models; significantly reverse the decrease in neurotransmitter levels caused by CUMS in mice, effectively increase the levels of GABA, 5-HT, DA, and NE in the serum of depressed mice; reduce serum TNF-α and IL-6 levels, and improve inflammatory factor levels.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention discloses an imaging and behavior correlation analysis method and system for mouse neuron activity, and relates to the technical field of optical imaging and neuroscience, and the method comprises the steps: synchronously collecting a brain region two-photon calcium imaging sequence and behavior data of a mouse when the mouse executes a behavior task; establishing identity mapping of the same neuron through an image registration and neuron tracking algorithm; deconvolving the calcium signal into a neuron pulse sequence, and performing time alignment with the behavior event; identifying a behavior-related neuron cluster, and analyzing dynamic evolution of an activity mode along with a training period; generating a hologram based on an analysis result, performing optical genetic intervention on a specific neuron cluster, and verifying causal association by comparing nerve and behavior data before and after intervention. According to the method, closed-loop research on the same neuron group in the long-term learning and memory process is realized, and the problems of difficulty in long-term tracking, low behavior synchronization precision and lack of precise causal verification means in the prior art are solved.

The invention relates to an application of TLR < 4 > siRNA (TLR < 4 > siRNA (at) LNP-CSA-BP) coated with TLR < 4 > siRNA (TLR < 4 > siRNA) connected with placental Chondroitin sulfate A binding peptide (Placental Chondroitin sulfate A binding peptide, CSA-BP) injected in a maternal pregnancy period, in improvement of pregnancy complications and prevention of progeny neurodevelopment disorder diseases, in particular to an application of TLR < 4 > siRNA coated with LNP-CSA-BP coated with TLR < 4 > siRNA coated with LNP-CSA-BP. According to the invention, TLR4siRNA (at) LNP-CSA-BP is used for carrying out caudal vein injection on a pregnant mouse, so that a placenta and fetal brain inflammation microenvironment (induced by toxoplasma gondii STAg) maternal immune activation can be inhibited. Behavior experiments further prove that under a maternal immune activation model, TLR4siRNA (at) LNP-CSA-BP caudal vein injection pregnant mice can significantly improve phenotypes of neurodevelopmental disorder diseases of filial generation mice, such as core symptoms (social ability and repeated engraving behaviors) of autism behaviors, and the promising transformation prospect is proved.

The present application relates to the technical field of Tibetan medicine, and particularly relates to application of a Tibetan medicine composition in preparation of a medicine for preventing and / or treating diabetic peripheral neuropathy, wherein the Tibetan medicine composition comprises the following raw medicines: turmeric, mace, sweet cinnamon, actinolite, licorice, artificial musk, dried ginger, Tibetan cumin, Tibetan aconite, Sichuan pepper and alkali flower, and the present application first discovers that the Tibetan medicine composition can improve the sensitivity of nerve endings of a diabetic peripheral nerve injury model mouse, relieve the symptoms of hypalgesia and limb numbness caused by diabetic peripheral nerve injury, and improve the motor nerve conduction velocity of the diabetic peripheral nerve injury model mouse, which indicates that the Tibetan medicine composition can prevent and / or treat diabetic peripheral nerve injury, prevent and / or treat diabetic peripheral neuropathy, and is a potential medicine for diabetic peripheral neuropathy.

The invention belongs to the technical field of biological medicine, and particularly relates to a TRPML1 specific small molecule agonist ML-SA5 and application thereof. The structural formula of the TRPML1 specific small molecule agonist ML-SA5 is as shown in the specification. The TRPML1 specific micromolecule agonist ML-SA5 has the beneficial effects that the TRPML1 specific micromolecule agonist ML-SA5 can be used for remarkably reducing the central nervous inflammation level of a depression model mouse; the mouse neuron excitability of the depression model is improved; depression-like behaviors of depression model mice are improved; the brain function of a depression model mouse is comprehensively protected; the TRPML1 specific micromolecule agonist ML-SA5 provided by the invention provides a new medicine for treating depression, and has good market value and clinical application prospect.

The application discloses application of Zanthoxylum amide in preparation of a drug for treating multiple sclerosis. The Zanthoxylum amide is selected from hydroxyl-alpha- toosendanin and hydroxyl-beta-toosendanin. Research results of the application show that hydroxyl-alpha-toosendanin and / or hydroxyl-beta-toosendanin has a good treatment effect on an experimental autoimmune encephalomyelitis mouse model. Compared with a model group, drug intervention can obviously improve nerve dysfunction and disability degree of the mouse, delay clinical symptoms, reduce inflammation of spinal cord tissue, regulate immune function, and show a good treatment effect. The application can provide a new drug for treating multiple sclerosis.

The invention belongs to the field of medicine synthesis, and relates to (2E, 4E)-N-cyclopropyldecyl-2, 4-dienamide as well as a preparation method and application of the (2E, 4E)-N-cyclopropyldecyl-2, 4-dienamide. The structure of the (2E, 4E)-N-cyclopropyldeca-2, 4-dienamide is shown as a formula I. The preparation method comprises the following steps: carrying out oxidation reaction on (2E, 4E)-2, 4-decadienal (compound II) to obtain a compound III, carrying out condensation reaction on the compound III and cyclopropylamine (compound IV) to obtain (2E, 4E)-N-cyclopropyldeca-2, 4-dienamide (compound I), and carrying out condensation reaction on the (2E, 4E)-N-cyclopropyldeca-2, 4-dienamide (compound I) and (2E, 4E)-N-cyclopropyldeca-2, 4-dienamide (compound II) to obtain the (2E, 4E)-N-cyclopropyldeca-2, 4-dienamide. The 2, 4-dienamide has the effect of preventing or treating nervous system related diseases, and in a pharmacodynamic test of a mouse neuralgia model, in a similar pain value range, the required dosage of the compound I is smaller than that of a contrast drug pregabalin.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain of combined lactobacillus salivarius and application thereof. Through a large number of screening and verification tests, the invention invents a strain of Lactobacillus salivarius 194-07 with strong growth activity, which can inhibit DPP4 activity, at the same time, in an anxiety mouse model, the expression in mouse open field central region movement and elevated cross maze movement can be significantly improved, and the mouse neurotransmitter level can be improved; the level of inflammatory factors in hippocampal tissues in the body and the brain is inhibited, and the safety is good. The strain disclosed by the invention has good application potential in the aspects of blood glucose control, mental diseases (anxiety disorder), nerve anti-inflammation and the like.

The application provides application of benzene sulfonamide in preparation of a medicine for treating peripheral nerve adhesion diseases, and relates to the biomedical technical field, and has the technical scheme as follows: the application of benzene sulfonamide in preparation of the medicine for treating peripheral nerve adhesion diseases, and the application is proved through specific verification experiments, specifically, the application systematically evaluates the influence of benzene sulfonamide on mouse nerve adhesion through various technical means such as direct observation on nerve adhesion and muscle atrophy, electrophysiological recording and behavior test, and successfully proves the positive effect of benzene sulfonamide on promoting recovery of adhesion nerves, improving motor balance ability and improving nerve conduction rate. These research results not only provide a solid scientific basis for benzene sulfonamide as a potential therapeutic drug, but also open up a new research direction for the treatment of peripheral nerve adhesion diseases.

This invention belongs to the field of traditional Chinese medicine technology and discloses a method for constructing an animal model of neuroinflammation intervention and screening effective components in turmeric residue. The method includes the following steps: S1: preparing experimental reagents for the animal model; S2: constructing a mouse model of Aβ1-42-induced neuroinflammation; S3: exploring the mechanism and effect of turmeric residue in intervening in mouse neuroinflammation. This invention also provides a method for screening effective components in turmeric residue, using an animal model of neuroinflammation intervention to screen for effective components in turmeric residue that intervene in neuroinflammation. This invention uses a specially constructed animal model, UPLC-MS / MS, HPLC, combined with non-targeted metabolomics technology to study the mechanism, effect, and effective components of turmeric residue in intervening in mouse neuroinflammation. It can be widely applied to the in-depth development of turmeric-based traditional Chinese medicine residues, effectively utilizing turmeric residue resources and providing support for the prevention and treatment of neuroinflammation-related diseases.

The invention provides amitriptyline hydrochloride emulsifiable paste as well as a preparation method and application thereof, and belongs to the technical field of medicines. The amitriptyline hydrochloride emulsion is prepared from the following components in parts by mass: 3 to 8 parts of amitriptyline hydrochloride, 5 to 10 parts of glycerol, 3 to 8 parts of octadecanol, 3 to 8 parts of hexadecanol, 0.5 to 2 parts of ethylparaben, 2 to 5 parts of white vaseline, 0.5 to 2 parts of lauryl sodium sulfate, 12 to 20 parts of dimeticone, 0.5 to 2 parts of laurocapram, 1 to 5 parts of OP-10 and 40 to 67.5 parts of water. When a neuropathic pain model mouse is smeared with the amitriptyline hydrochloride emulsifiable paste, the symptom of the neuropathic pain of the mouse can be improved, the amitriptyline hydrochloride emulsifiable paste can quickly play a role in easing pain, and repair of injured nerves can be promoted through long-term administration.